CRISPR Unlocks Sweeter Tomatoes Without Yield Loss
Carbon
Nov. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Akribion Genomics
Company Type: CRO
Main focus: Discovery and engineering of novel nucleases
Company stage: Pre-clinical
Diseases: Cancer
Genome-editing tool: Proprietary G-dases® nucleases
Funding stage: sub-section of BRAIN Biotech AG (IPO: BNN)
Location: Zwingenberg, Germany
Website: https://www.akribion-genomics.com/
Pipeline:
Partners: BRAIN Biotech AG
As a brand name of BRAIN Biotech AG, Akribion Genomics focuses on developing novel CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome-editing tools, powered by the BRAIN Biotech AG BioIncubator. Akribion Genomics’ CRISPR-based gene-editing technology platform features distinct technology families (G-dases®) with broad application in Industrial Biotechnology and Agriculture.
